• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Athenex Inc.

Headquarters: Buffalo, NY, United States
Website: N/A
Year Founded: 2002
Status: Out of Business

BioCentury | Aug 9, 2023
Management Tracks

AI Proteins names Noah Beerman as CEO, Alles chair 

Plus: Emergent cuts include COO, and updates from Playground, Viracta, Dunad 
Read More
BioCentury | Jun 8, 2022
Management Tracks

NIBR’s Marks joins GV as entrepreneur-in-residence

Plus new venture partner and promotions at Arch, and updates from IQVia, Emergence and more
Read More
BioCentury | May 20, 2022
Product Development

Next-gen NK cell enhancements in the clinic

Companies are turning to tumor targeting, IL-15 expression and alternate cell sourcing to boost the potency and longevity of NK cell therapies
Read More
BioCentury | Feb 23, 2022
Management Tracks

Gerngross resigns as Adagio CEO

Plus Shah steps down as CMO at Karyopharm; updates from Meridian, HanAll and more
Read More
BioCentury | Jan 15, 2022
Management Tracks

Founder El-Hibri to retire from Emergent

Plus CEO Sandanayaka shifts to CSO at Nirogy, and updates from Angelini, Apie, 
Read More
BioCentury | Oct 19, 2021
Management Tracks

Carl June joins Bioheng’s SAB

Plus: Myriad, Kura, Ideaya, IASO, OncoCyte and more
Read More
BioCentury | Sep 1, 2021
Management Tracks

Zaks joins board at Teva

Jogerst named CBO at Rubius, plus updates from Telix, Talis, Ziopharm, Pyxis and more
Read More
BioCentury | Jul 22, 2021
Deals

July 21 Quick Takes: Turnstone’s $80M round to advance oncolytic virus, TIL programs

Plus: Vedanta, bluebird, Cytokinetics and more
Read More
BioCentury | May 11, 2021
Emerging Company Profile

Baltimore and colleagues launch NKT cell company Appia 

Emerging Company Profile: Appia emerged from stealth with $52 million and a platform to scale iNKT cell production
Read More
BioCentury | May 5, 2021
Deals

Athenex pushes further into cell therapy with Kuur acquisition

Two months after a regulatory setback for Athenex’s most advanced pipeline program, the biotech is pivoting further into cell therapy through the acquisition of Kuur, which itself had run into
Read More
Items per page:
1 - 10 of 44